T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93

Neil Elliot Kay, Traci Leong, Nancy Bone, Robert A. Kyle, Phillip R. Greipp, Brian Van Ness, Martin M. Oken

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

T-helper blood populations are frequently altered in multiple myeloma (MM). We measured the numbers of naive and activated cell subsets in the blood of a cohort of both previously untreated and treated MM patients. Two- colour flow cytometry to detect total CD4+, CD4+, CD45RA+ (naive) and CD4+, CD45RO+ (activated) subsets was then used to quantify the T-cell subsets in controls and MM patients. Previously treated MM patients either on or off treatment (n = 105) had significantly reduced (P < 0.0001) total CD4 and naive/activated cells than controls. Previously treated MM patients sampled for naive/activated cells while currently off therapy (n = 45) had no difference in the levels of CD4 and naive/activated cells compared to the currently treated patients (n = 60). However, newly diagnosed patients (n = 58) had a significantly reduced total CD4 (P = 0.023) and activated CD4 (P = 0.004), but not naive CD4 subsets, compared to controls. CD19+ cell levels above 125/μl were positively associated with higher T-helper cell levels. There was a strong positive association for better overall survival for patients with >395 CD4 cells/μl (P=0.0001). These data indicate that MM patients at diagnosis have altered T helper subsets, with a selective reduction in activated but not naive cells. Subsequent chemotherapy or the disease process contributes to a further reduction in CD4 cells. Importantly, the association of higher CD19+ cell levels with higher T helper cells indicates that certain myeloma patients can be identified with a more quantitatively intact immune system.

Original languageEnglish (US)
Pages (from-to)459-463
Number of pages5
JournalBritish Journal of Haematology
Volume100
Issue number3
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Multiple Myeloma
Phenotype
T-Lymphocyte Subsets
Helper-Inducer T-Lymphocytes
Immune System
Flow Cytometry
Color
Drug Therapy
Population
Therapeutics

Keywords

  • Myeloma
  • Survival
  • T cells
  • T-helper subsets
  • Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. / Kay, Neil Elliot; Leong, Traci; Bone, Nancy; Kyle, Robert A.; Greipp, Phillip R.; Van Ness, Brian; Oken, Martin M.

In: British Journal of Haematology, Vol. 100, No. 3, 1998, p. 459-463.

Research output: Contribution to journalArticle

Kay, Neil Elliot ; Leong, Traci ; Bone, Nancy ; Kyle, Robert A. ; Greipp, Phillip R. ; Van Ness, Brian ; Oken, Martin M. / T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. In: British Journal of Haematology. 1998 ; Vol. 100, No. 3. pp. 459-463.
@article{26ccfef55b9e4e8c9ee9ba020b1addd7,
title = "T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93",
abstract = "T-helper blood populations are frequently altered in multiple myeloma (MM). We measured the numbers of naive and activated cell subsets in the blood of a cohort of both previously untreated and treated MM patients. Two- colour flow cytometry to detect total CD4+, CD4+, CD45RA+ (naive) and CD4+, CD45RO+ (activated) subsets was then used to quantify the T-cell subsets in controls and MM patients. Previously treated MM patients either on or off treatment (n = 105) had significantly reduced (P < 0.0001) total CD4 and naive/activated cells than controls. Previously treated MM patients sampled for naive/activated cells while currently off therapy (n = 45) had no difference in the levels of CD4 and naive/activated cells compared to the currently treated patients (n = 60). However, newly diagnosed patients (n = 58) had a significantly reduced total CD4 (P = 0.023) and activated CD4 (P = 0.004), but not naive CD4 subsets, compared to controls. CD19+ cell levels above 125/μl were positively associated with higher T-helper cell levels. There was a strong positive association for better overall survival for patients with >395 CD4 cells/μl (P=0.0001). These data indicate that MM patients at diagnosis have altered T helper subsets, with a selective reduction in activated but not naive cells. Subsequent chemotherapy or the disease process contributes to a further reduction in CD4 cells. Importantly, the association of higher CD19+ cell levels with higher T helper cells indicates that certain myeloma patients can be identified with a more quantitatively intact immune system.",
keywords = "Myeloma, Survival, T cells, T-helper subsets, Therapy",
author = "Kay, {Neil Elliot} and Traci Leong and Nancy Bone and Kyle, {Robert A.} and Greipp, {Phillip R.} and {Van Ness}, Brian and Oken, {Martin M.}",
year = "1998",
doi = "10.1046/j.1365-2141.1998.00609.x",
language = "English (US)",
volume = "100",
pages = "459--463",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93

AU - Kay, Neil Elliot

AU - Leong, Traci

AU - Bone, Nancy

AU - Kyle, Robert A.

AU - Greipp, Phillip R.

AU - Van Ness, Brian

AU - Oken, Martin M.

PY - 1998

Y1 - 1998

N2 - T-helper blood populations are frequently altered in multiple myeloma (MM). We measured the numbers of naive and activated cell subsets in the blood of a cohort of both previously untreated and treated MM patients. Two- colour flow cytometry to detect total CD4+, CD4+, CD45RA+ (naive) and CD4+, CD45RO+ (activated) subsets was then used to quantify the T-cell subsets in controls and MM patients. Previously treated MM patients either on or off treatment (n = 105) had significantly reduced (P < 0.0001) total CD4 and naive/activated cells than controls. Previously treated MM patients sampled for naive/activated cells while currently off therapy (n = 45) had no difference in the levels of CD4 and naive/activated cells compared to the currently treated patients (n = 60). However, newly diagnosed patients (n = 58) had a significantly reduced total CD4 (P = 0.023) and activated CD4 (P = 0.004), but not naive CD4 subsets, compared to controls. CD19+ cell levels above 125/μl were positively associated with higher T-helper cell levels. There was a strong positive association for better overall survival for patients with >395 CD4 cells/μl (P=0.0001). These data indicate that MM patients at diagnosis have altered T helper subsets, with a selective reduction in activated but not naive cells. Subsequent chemotherapy or the disease process contributes to a further reduction in CD4 cells. Importantly, the association of higher CD19+ cell levels with higher T helper cells indicates that certain myeloma patients can be identified with a more quantitatively intact immune system.

AB - T-helper blood populations are frequently altered in multiple myeloma (MM). We measured the numbers of naive and activated cell subsets in the blood of a cohort of both previously untreated and treated MM patients. Two- colour flow cytometry to detect total CD4+, CD4+, CD45RA+ (naive) and CD4+, CD45RO+ (activated) subsets was then used to quantify the T-cell subsets in controls and MM patients. Previously treated MM patients either on or off treatment (n = 105) had significantly reduced (P < 0.0001) total CD4 and naive/activated cells than controls. Previously treated MM patients sampled for naive/activated cells while currently off therapy (n = 45) had no difference in the levels of CD4 and naive/activated cells compared to the currently treated patients (n = 60). However, newly diagnosed patients (n = 58) had a significantly reduced total CD4 (P = 0.023) and activated CD4 (P = 0.004), but not naive CD4 subsets, compared to controls. CD19+ cell levels above 125/μl were positively associated with higher T-helper cell levels. There was a strong positive association for better overall survival for patients with >395 CD4 cells/μl (P=0.0001). These data indicate that MM patients at diagnosis have altered T helper subsets, with a selective reduction in activated but not naive cells. Subsequent chemotherapy or the disease process contributes to a further reduction in CD4 cells. Importantly, the association of higher CD19+ cell levels with higher T helper cells indicates that certain myeloma patients can be identified with a more quantitatively intact immune system.

KW - Myeloma

KW - Survival

KW - T cells

KW - T-helper subsets

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0031864211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031864211&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1998.00609.x

DO - 10.1046/j.1365-2141.1998.00609.x

M3 - Article

C2 - 9504626

AN - SCOPUS:0031864211

VL - 100

SP - 459

EP - 463

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -